TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas

Exp Cell Res. 2023 Mar 1;424(1):113474. doi: 10.1016/j.yexcr.2023.113474. Epub 2023 Jan 23.

Abstract

Glioma is a common type of brain tumor with high incidence and mortality rates. Iron plays an important role in various physiological and pathological processes. Iron entry into the cell is promoted by binding the transferrin receptor 2 (TFR2) to the iron-transferrin complex. This study was designed to assess the association between TFR2 and ferroptosis in glioma. Lipid peroxidation levels in glioma cells were assessed by determination of lipid reactive oxygen species (ROS), glutathione content, and mitochondrial membrane potential. The effect of TFR2 on TMZ sensitivity was examined by cell viability assays, flow cytometry, and colony formation assays. We found that Low TFR2 expression predicted a better prognosis for glioma patients. And overexpression of TFR2 promoted the production of reactive oxygen species and lipid peroxidation in glioma cells, thereby further promoting ferroptosis. This could be reversed by the ferroptosis inhibitors Fer-1 and DFO (both inhibitors of ferroptosis). Moreover, TFR2 potentiated the cytotoxic effect of TMZ (temozolomide) via activating ferroptosis. In conclusion, we found that TFR2 induced ferroptosis and enhanced TMZ sensitivity in gliomas. Our findings might provide a new treatment strategy for glioma patients and improve their prognosis.

Keywords: Ferroptosis; Glioma; Prognosis; TFR2; Temozolomide.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Ferroptosis*
  • Glioma* / drug therapy
  • Glioma* / genetics
  • Glioma* / metabolism
  • Humans
  • Iron / metabolism
  • Reactive Oxygen Species / metabolism
  • Receptors, Transferrin / genetics
  • Temozolomide / pharmacology

Substances

  • Temozolomide
  • Reactive Oxygen Species
  • Iron
  • TFR2 protein, human
  • Receptors, Transferrin